ENTA

EDP-938

Respiratory Syncytial Virus (RSV)

Stage (next event)

Expected Date

Phase 2 Initiation

Q4 2020

Catalyst Info & Data Links

TITLE: EDP-938  in Respiratory Syncytial Virus (RSV) - Phase 2 


WHAT IS THE CATALYST EVENT?

  • Initiate two Phase 2 RSV studies in pediatric and transplant patients 4Q 2020

  • Data from RSVP Phase 2b adult outpatient study 3Q 2021


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • December 31, 2020 (Est)


PRIOR DATA/EVENTS

PRESS RELEASE

Mechanism of Action

MECHANISM OF ACTION

  • EDP-938, Enanta’s lead N-protein inhibitor, is being developed for the treatment of RSV infection. Enanta believes EDP-938 is differentiated from fusion inhibitors currently in development by others for RSV because this N-protein inhibitor targets the virus’ replication machinery and has demonstrated high barriers to resistance against the virus in vitro. EDP-938 has also been shown to reduce viral load below the level of detection in vivo. Additionally, it is possible that N-protein inhibitors may be effective treatments at later stages of infection.

Updated by JM 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

ARQL 531 - Blood Cancer Promise and Fuel for ARQL Investors

FDA Decision on Heron's Non-Opioid Pain Med Imminent

Amp Core Q2 '19 Report

Incyte (INCY) appears to have the stronger hand in its patent disputes with Concert (CNCE), regardle

FDA Accepts AIMT's Peanut Allergy Treatment BLA For Review

Cara Therapeutics - Itching For Big Returns In 2019

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon